ELUT - CIK 0001708527
ELUTIA INC. trades as ELUT. In its fiscal 2025 annual report the company posted revenue of $12.29M, down 15.0% from the prior year and net income of $53.38M. This page tracks ELUTIA INC. through 348 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 6 fiscal years ELUTIA INC.'s revenue declined from $42.90M to $12.29M, a compound annual decline rate of 18.8%. Net profit margin expanded from -27.8% to 434.2% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Quarterly report | 10-Q | 2026-05-15 |
| Major company event | 8-K | 2026-05-14 |
| Annual report to shareholders | ARS | 2026-04-22 |
| Proxy materials | DEFA14A | 2026-04-22 |
| Proxy statement | DEF 14A | 2026-04-22 |
| Insider trade | 4 | 2026-04-14 |
| Employee stock plan | S-8 | 2026-03-25 |
| Annual report | 10-K | 2026-03-13 |
The largest companies sharing ELUTIA INC.'s SEC industry classification (biological products, (no diagnostic substances)).
ELUTIA INC. reported revenue of $12.29M for fiscal year 2025, a decrease of 15.0% year over year.
Yes. ELUTIA INC. reported net income of $53.38M in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.